Stock Analysts’ updated eps estimates for Tuesday, August 8th:

Atlas Financial Holdings (NASDAQ:AFH) had its buy rating reaffirmed by analysts at Boenning Scattergood. The analysts wrote, “We are raising our estimates and target price, and maintaining our Outperform rating.””

Stifel Nicolaus initiated coverage on shares of Akcea Therapeut (NASDAQ:AKCA). The firm issued a buy rating and a $19.00 price target on the stock.

Cowen and Company started coverage on shares of Akcea Therapeut (NASDAQ:AKCA). Cowen and Company issued an outperform rating on the stock.

Wells Fargo & Company started coverage on shares of Akcea Therapeut (NASDAQ:AKCA). The firm issued an outperform rating on the stock.

Barclays PLC assumed coverage on shares of Brighthouse Financial (NYSE:BHF). They issued an overweight rating on the stock.

Citigroup Inc. initiated coverage on shares of Century Communities (NYSE:CCS). The firm issued a buy rating on the stock.

Ceragon Networks (NASDAQ:CRNT) had its hold rating reaffirmed by analysts at Oppenheimer Holdings, Inc..

Second Sight Medical Products (NASDAQ:EYES) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $5.00 price target on the stock. The analysts wrote, “We expect that the second pilot study could start in late 3Q17 or early 4Q17 and report top-line data by the end of 2017. Investors may recall that this second pilot study is double-masked and slated to enroll up to 45 subjects. The primary endpoint is the percentage of subjects achieving complete wound healing (based on staining) on day 3. Assuming that the second pilot study shows OBG’s ability to heal corneal defects faster than the standard of care, as was seen in the first pilot study, we believe that EyeGate may only need to conduct a single pivotal study in 2018 before filing for regulatory approval. We note that the FDA has permitted EyeGate to pursue U.S. regulatory clearance for OBG through the de novo 510(k) pathway.””

FibroGen (NASDAQ:FGEN) had its buy rating reissued by analysts at Jefferies Group LLC.

Morgan Stanley initiated coverage on shares of General Dynamics Corporation (NYSE:GD). The firm issued a sell rating and a $185.00 target price on the stock.

Hargreaves Services plc (LON:HSP) had its buy rating reissued by analysts at Investec. The firm currently has a GBX 491 ($6.39) target price on the stock.

Hydrogenics Corporation (NASDAQ:HYGS) (TSE:HYG) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $10.00 price target on the stock.

Morgan Stanley started coverage on shares of Lockheed Martin Corporation (NYSE:LMT). They issued a buy rating and a $342.00 target price on the stock.

Main Street Capital Corporation (NYSE:MAIN) had its sell rating reiterated by analysts at National Securities. They currently have a $33.00 target price on the stock. The analysts wrote, “• In 2Q17 NII/share was $0.58/share compared to our estimate of $0.56 and consensus estimates of $0.54. Fee income was up 26% linked Q/Q to $3.1 million with approximately $0.02/share of fee income during the quarter considered nonrecurring in nature.

• Despite being a very strong originator with good asset quality and shareholder friendly actions and structure we note that current valuation represents a 76% premium to NAV/share and 67% to our 4Q18 NAV/share estimate. Our $33 price target represents a tailing P/NAV (trailing) of 1.46x and 1.38x P/NAV (4Q18E). We think the market is discounting that dislocations in the markets, especially given the age of the credit cycle, could materially lower company valuation multiples which, if to the magnitude of getting rid of realized gains dividends, would materially lower the total yield and weigh on the valuation significantly, in our view. We regard Main Street as a top performer in the sector from an operational perspective, but we believe that shares are currently valued far too high.

• We are revising our 2017 NII/share estimate to $2.31 from $2.27 from $2.35 and our 2018 NII/share estimate to $2.42 from $2.37.”

Maxwell Technologies (NASDAQ:MXWL) had its hold rating reissued by analysts at Oppenheimer Holdings, Inc..

Morgan Stanley started coverage on shares of Northrop Grumman Corporation (NYSE:NOC). They issued a hold rating and a $279.00 price target on the stock.

Performance Food Group (NYSE:PFGC) had its buy rating reissued by analysts at Wells Fargo & Company.

ProAssurance Corporation (NYSE:PRA) had its hold rating reissued by analysts at Boenning Scattergood.

Quantenna Comms (NASDAQ:QTNA) had its buy rating reaffirmed by analysts at Needham & Company LLC. The analysts wrote, “QTNA delivered its third consecutive beat and raise quarter as a public company driven by strong shipments across each of its product offerings. QTNA is deploying its Wave 2 solutions across new and existing service provider customers driven by increasing consumer demand for high performance WiFi. QSR10G Wave 3 revenue grew 66% Q/Q in 2Q17 and is poised for strong growth in 2H17 driven by service launches at multiple MSOs. QTNA now expects Wave 3 solutions to be no less than 10% of sales in 3Q.””

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its neutral rating reaffirmed by analysts at HC Wainwright. They currently have a $75.00 price target on the stock, up from their previous price target of $72.00.

Morgan Stanley initiated coverage on shares of Raytheon (NYSE:RTN). The firm issued a buy rating and a $188.00 price target on the stock.

Synthomer PLC (LON:SYNT) had its buy rating reissued by analysts at Canaccord Genuity. They currently have a GBX 500 ($6.51) target price on the stock.

Receive News & Ratings for Atlas Financial Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlas Financial Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.